Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Assets: 2009-2024

Historic Current Assets for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $4.1 million.

  • Northwest Biotherapeutics' Current Assets rose 38.64% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 38.64%. This contributed to the annual value of $4.1 million for FY2024, which is 1.53% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Current Assets stood at $4.1 million for FY2024, which was down 1.53% from $4.1 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' Current Assets peaked at $17.3 million during FY2021, and registered a low of $4.1 million during FY2024.
  • Over the past 3 years, Northwest Biotherapeutics' median Current Assets value was $4.1 million (recorded in 2023), while the average stood at $5.9 million.
  • In the last 5 years, Northwest Biotherapeutics' Current Assets spiked by 384.72% in 2020 and then plummeted by 56.23% in 2023.
  • Northwest Biotherapeutics' Current Assets (Yearly) stood at $15.5 million in 2020, then grew by 11.47% to $17.3 million in 2021, then plummeted by 45.49% to $9.4 million in 2022, then plummeted by 56.23% to $4.1 million in 2023, then fell by 1.53% to $4.1 million in 2024.